Adam Maeder
Stock Analyst at Piper Sandler
(3.34)
# 1,010
Out of 5,122 analysts
106
Total ratings
45.83%
Success rate
5.36%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Adam Maeder
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RMD ResMed | Maintains: Neutral | $270 → $275 | $251.41 | +9.38% | 5 | Jan 30, 2026 | |
| ISRG Intuitive Surgical | Maintains: Overweight | $610 → $620 | $478.88 | +29.47% | 22 | Jan 23, 2026 | |
| ABT Abbott Laboratories | Maintains: Overweight | $150 → $135 | $109.02 | +23.83% | 4 | Jan 23, 2026 | |
| RXST RxSight | Maintains: Neutral | $10 → $11 | $8.34 | +31.89% | 3 | Jan 20, 2026 | |
| EW Edwards Lifesciences | Maintains: Overweight | $95 → $98 | $82.10 | +19.37% | 18 | Jan 20, 2026 | |
| TCMD Tactile Systems Technology | Upgrades: Overweight | $20 → $35 | $28.22 | +24.03% | 5 | Jan 5, 2026 | |
| SGHT Sight Sciences | Upgrades: Overweight | $5 → $9 | $6.47 | +39.10% | 3 | Jan 5, 2026 | |
| INSP Inspire Medical Systems | Maintains: Overweight | $135 → $165 | $72.10 | +128.85% | 17 | Dec 8, 2025 | |
| NYXH Nyxoah | Reiterates: Overweight | $12 → $9 | $4.62 | +94.81% | 9 | Nov 14, 2025 | |
| RBOT Vicarious Surgical | Maintains: Neutral | $8.5 → $7 | $2.07 | +238.16% | 8 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $4.5 → $4 | $1.64 | +143.90% | 4 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $20 → $21 | $21.23 | -1.08% | 2 | May 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $7 → $8 | $1.82 | +339.56% | 1 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $6 → $5 | $2.18 | +129.36% | 2 | Mar 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $104 → $99 | $65.93 | +50.16% | 3 | May 5, 2022 |
ResMed
Jan 30, 2026
Maintains: Neutral
Price Target: $270 → $275
Current: $251.41
Upside: +9.38%
Intuitive Surgical
Jan 23, 2026
Maintains: Overweight
Price Target: $610 → $620
Current: $478.88
Upside: +29.47%
Abbott Laboratories
Jan 23, 2026
Maintains: Overweight
Price Target: $150 → $135
Current: $109.02
Upside: +23.83%
RxSight
Jan 20, 2026
Maintains: Neutral
Price Target: $10 → $11
Current: $8.34
Upside: +31.89%
Edwards Lifesciences
Jan 20, 2026
Maintains: Overweight
Price Target: $95 → $98
Current: $82.10
Upside: +19.37%
Tactile Systems Technology
Jan 5, 2026
Upgrades: Overweight
Price Target: $20 → $35
Current: $28.22
Upside: +24.03%
Sight Sciences
Jan 5, 2026
Upgrades: Overweight
Price Target: $5 → $9
Current: $6.47
Upside: +39.10%
Inspire Medical Systems
Dec 8, 2025
Maintains: Overweight
Price Target: $135 → $165
Current: $72.10
Upside: +128.85%
Nyxoah
Nov 14, 2025
Reiterates: Overweight
Price Target: $12 → $9
Current: $4.62
Upside: +94.81%
Vicarious Surgical
Aug 13, 2025
Maintains: Neutral
Price Target: $8.5 → $7
Current: $2.07
Upside: +238.16%
May 12, 2025
Maintains: Overweight
Price Target: $4.5 → $4
Current: $1.64
Upside: +143.90%
May 22, 2024
Maintains: Hold
Price Target: $20 → $21
Current: $21.23
Upside: -1.08%
Mar 6, 2024
Reiterates: Overweight
Price Target: $7 → $8
Current: $1.82
Upside: +339.56%
Mar 6, 2023
Maintains: Overweight
Price Target: $6 → $5
Current: $2.18
Upside: +129.36%
May 5, 2022
Maintains: Overweight
Price Target: $104 → $99
Current: $65.93
Upside: +50.16%